Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by J. A Jung
Total Records ( 1 ) for J. A Jung
  J. A Jung , B. M Choi , S. H Cho , S. M Choe , J. L Ghim , H. M Lee , Y. J Roh and G. J. Noh

The aims of this study were to investigate the effectiveness, safety, pharmacokinetics, and pharmacodynamics of microemulsion propofol, AquafolTM (Daewon Pharmaceutical Co., Ltd, Seoul, Republic of Korea).


In total, 288 patients were randomized to receive 1% AquafolTM or 1% Diprivan® (AstraZeneca, London, UK) (n=144, respectively). A 30 mg test dose of propofol was administered i.v. over 2 s for assessing injection pain. Subsequently, a bolus of propofol 2 mg kg–1 (–30 mg) was administered. Anaesthesia was maintained with a variable rate infusion of propofol and a target-controlled infusion of remifentanil. Mean infusion rates of both formulations and times to loss of consciousness (LOC) and recovery of consciousness (ROC) were recorded. Adverse events and pharmacokinetic and pharmacodynamic characteristics were evaluated.


Mean infusion rate of AquafolTM was not statistically different from that of Diprivan® (median: 6.2 vs 6.3 mg kg–1 h–1). Times to LOC and ROC were slightly prolonged in AquafolTM (median: 21 vs 18 s, 12.3 vs 10.8 min). AquafolTM showed similar incidence of adverse events to Diprivan®. AquafolTM (vs Diprivan®) caused more severe (median VAS: 72.0 vs 11.5 mm) and frequent (81.9 vs 29.2%) injection pain. The dose-normalized AUClast of AquafolTM and Diprivan® was 0.71 (0.19) and 0.74 (0.20) min litre–1. The V1 of both formulations were proportional to lean body mass. Sex was a significant covariate for k12 and Ce50 of AquafolTM, and for ke0 of Diprivan®.


AquafolTM was as effective and safe as Diprivan®, but caused more severe and frequent injection pain. AquafolTM demonstrated similar pharmacokinetics to Diprivan®.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility